Drug Trial Radar · NCT02675465
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Apr 2016
Primary completion
Aug 22, 2024
Study completion Aug 22, 2024
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
Conditions
- Pompe Disease
Interventions
ATB200Drug
AT2221Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events (AEs) Leading to Discontinuation of Study DrugTime frame: Stage 3 (2 year treatment) and Stage 4 (Extension) combined, (mean = 71 months on treatment)
- Plasma Human Acid α-glucosidase (GAA) Activity Levels as Measured by Maximum Observed Plasma Concentration (Cmax).Time frame: 18 Weeks
- Plasma GAA Activity Levels as Measured by Time to Reach the Maximum Observed Plasma Concentration (Tmax).Time frame: 18 Weeks
- Plasma GAA Activity Levels as Measured by Area Under the Plasma Drug Concentration-time Curve (AUC).Time frame: 18 Weeks
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
Neuromuscular Research Centre
Phoenix, Arizona
University of California Irvine
Orange, California
University of Florida
Gainesville, Florida
Emory University Division of Medical Genetics
Decatur, Georgia
Infusion Associates
Grand Rapids, Michigan
Great Falls Clinic, LLP
Great Falls, Montana
Rutgers New Jersey Medical School
Newark, New Jersey
Duke University Medical Center
Durham, North Carolina
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Abramson Cancer Center Chester County Hospital
West Chester, Pennsylvania
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia
Womens & Childrens Hospital, Adelaide
North Adelaide, South Australia, Australia
University Children's Hospital Department of Neuropediatrics and Inborn Metabolic Disorders, St. Josefs-Hospital
Bochum, Germany
Friedrich-Baur-Institure, Dep of Neurology - University Munich
Munich, Germany
Erasmus Medical Center
Rotterdam, Netherlands
School of Medicine, University of Auckland
Auckland, New Zealand
University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Medical Center
Birmingham, United Kingdom
Salford Royal NHS Foundation Trust
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.